Surgical Robotics in Modern Oncology: Precision, Promise, and Pragmatism

Nirmal Lamichhane[1]
[1]Department of Urology, B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal

The field of surgical oncology has undergone a profound transformation with the advent of minimally invasive techniques, and more recently, robotic-assisted surgery. Building upon the foundations of laparoscopy, robotic platforms such as the da Vinci Surgical System have introduced enhanced dexterity, three-dimensional visualization, and improved ergonomics, redefining surgical precision in oncologic care[1].

Robotic surgery has rapidly gained acceptance across multiple oncologic disciplines, particularly in urologic, gynecologic, and colorectal malignancies. Its technological advantages—including tremor filtration, wristed instrumentation, and superior visualization—enable meticulous dissection in anatomically constrained regions such as the pelvis and mediastinum[2]. These features are especially relevant in cancer surgery, where achieving negative margins and preserving critical structures are paramount.

Emerging evidence from randomized trials and meta-analyses supports the clinical utility of robotic surgery in selected oncologic settings. The recent REAL randomized trial in rectal cancer demonstrated improved locoregional control and disease-free survival with robotic-assisted surgery compared to laparoscopy[3]. Similarly, systematic reviews have shown that robotic approaches achieve at least equivalent oncologic outcomes—including margin status and lymph node yield—when compared with conventional laparoscopic or open techniques[4].

In addition to oncologic equivalence, robotic surgery offers several perioperative advantages. Meta-analyses of randomized controlled trials have demonstrated reduced blood loss, lower conversion rates to open surgery, fewer postoperative complications, and faster recovery following robotic procedures[5]. Functional outcomes, particularly in uro-oncology, may also be improved, likely due to enhanced nerve preservation during precise dissection[6]. These benefits are particularly relevant in the multidisciplinary management of cancer patients, as earlier recovery may facilitate timely initiation of adjuvant therapies.

Despite these advantages, the widespread adoption of robotic surgery remains constrained by significant challenges. High capital and maintenance costs, increased operative times, and concerns regarding cost-effectiveness continue to limit accessibility, particularly in low- and middle-income countries such as Nepal. Current evidence suggests that while robotic surgery is safe and feasible, its economic impact is substantial, with few studies demonstrating clear cost-benefit superiority over conventional approaches[4].

Furthermore, long-term oncologic outcomes remain incompletely defined across many tumor types. While short-term benefits are increasingly evident, robust data on overall survival and recurrence patterns are still evolving. The heterogeneity of available studies and the relative paucity of large randomized trials underscore the need for continued research and high-quality evidence generation[4].

Training and credentialing represent additional critical considerations. The transition to robotic surgery requires structured training programs, simulation-based learning, and ongoing proficiency assessment to ensure patient safety and optimal outcomes[2]. Institutions adopting robotic platforms must balance technological enthusiasm with a commitment to evidence-based practice and surgical competence.

Looking ahead, the integration of robotic surgery with artificial intelligence, augmented reality, and image-guided navigation holds the potential to further enhance precision and intraoperative decision-making. As new robotic platforms emerge, increased competition may also drive down costs and improve accessibility, particularly in resource-constrained settings.

In conclusion, robotic surgery represents a significant advancement in modern surgical oncology, offering enhanced precision and promising perioperative outcomes. However, its role must be contextualized within considerations of cost, accessibility, and

evidence-based benefit. A judicious, patient-centered approach—supported by ongoing research and equitable resource allocation—will be essential to fully realize the potential of surgical robotics in oncology.

References

1. Hu Y, Strong VE. Robotic surgery and oncologic outcomes. *JAMA Oncol*. 2020.
2. Steffens D, Thanigasalam R, Leslie S, et al. Robotic surgery in uro-oncology: a systematic review and meta-analysis of randomized controlled trials. *Urology*. 2017;106:9–17.
3. Sidaway P. Robot-assisted laparoscopic surgery confers improved oncological outcomes. *Nat Rev Clin Oncol*. 2025;22:623.
4. What do randomized trials reveal about robotic surgery? A critical appraisal across specialties. 2025 review.
5. Mirza W, Dadan S, Khan HM, et al. Robotic versus laparoscopic surgery for rectal cancer: systematic review and meta-analysis of randomized trials. *Updates Surg*. 2025.
6. Outcomes of robot-assisted surgery in rectal cancer compared with open and laparoscopic surgery. *Ann Surg*. 2023.